Summary of SAVIENT PHARMACEUTICALS INC

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d) On June 4, 2009, the Board of Directors (the "Board") of Savient Pharmaceuticals, Inc. (the "Company"), based upon the recommendation of the Board's Nominating and Corporate Governance Committee, elected Dr. Ginger Constantine, M.D. to serve on the Company's Board of Directors. In connection with the election, the Board expanded the size of the Board to seven directors. Dr. Constantine will serve for a term expiring at the Company's annual meeting of stockholders in 2010 and until her successor shall have been elected and qualified or until her earlier resignation or removal.

Dr. Constantine, age 54, currently serves as Vice President of Women's Health & Bone Repair Medical Research at Wyeth Research, a division of Wyeth Pharmaceuticals, and has held Vice President positions with Wyeth since 2000.

There is no agreement or understanding between Dr. Constantine and any other person pursuant to which Dr. Constantine was appointed to the Board. Dr. Constantine is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Board has appointed Dr. Constantine to serve on its Nominating and Corporate Governance Committee.

Dr. Constantine shall receive compensation for serving on the Board and its committees pursuant to the Board compensation plan that was previously disclosed in the Company's filings with the SEC.

The full text of the press release issued in connection with Dr. Constantine's election to the Board is furnished as Exhibit 99.1 to this Current Report on Form 8-K.